Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.

Cancer genetics and cytogenetics - 1 Dec 2008

Haferlach Claudia, Bacher Ulrike, Tiu Ramon, Maciejewski Jaroslaw P, List Alan

Abstract excerpt

Cytogenetics is a major predictor of disease behavior and treatment outcome in myelodysplastic syndromes (MDS). Deletion of the long arm of chromosome 5, del(5q), is the most common chromosomal abnormality found in patients with MDS. The development of lenalidomide (Revlimid; Celgene, Summit, NJ) as an effective targeted therapy for low/intermediate-risk MDS with a del(5q) has increased the importance of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosome Deletion
Share to Chromosomes, Human, Pair 5

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytogenetic Analysis

Share to In Situ Hybridization, Fluorescence

Share to Lenalidomide

Share to Myelodysplastic Syndromes

Share to Nucleic Acid Hybridization

Share to Thalidomide

Source

Identifiers

PMID: 19027491
DOI: 10.1016/j.cancergencyto.2008.08.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.PMID 19027491Read ↗

Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid MalignanciesSemantic proximity Read ↗

Clinical Management of Myelodysplastic Syndromes With Interstitial Deletion of Chromosome 5qSemantic proximity Read ↗

Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.Semantic proximity Read ↗

A decade of progress in myelodysplastic syndrome with chromosome 5q deletion.Semantic proximity Read ↗

Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromesSemantic proximity Read ↗

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.Semantic proximity Read ↗

Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.Semantic proximity Read ↗

Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II studySemantic proximity Read ↗

A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q, 50 years after its discoverySemantic proximity Read ↗

Deletion 5q MDS: molecular and therapeutic implications.Semantic proximity Read ↗

Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.Semantic proximity Read ↗

Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.